

Special Issue

Safety, Efficacy and Optimization of the COVID-19 Vaccines

Message from the Guest Editor

Among the means of public health intervention, vaccination is both the most effective and cost-effective, with profound implications. The epidemic situation slows down with the emergency use of multiple COVID-19 vaccines; however, the validity of vaccines is being challenged by the constant emergence of new variants. Meanwhile, the safety in mass vaccination remains to be determined because of the short time-on-market of the vaccines. Therefore, there is still a long way to go to extinguish the COVID-19 epidemic. In this Special Issue, we aim to seek a better vaccine design scheme and optimize vaccination strategies by summarizing the influencing factors that impact the safety and efficacy of the different vaccines (inactivated vaccines, adenovirus-vectored vaccines, and nucleic acid vaccines), including design principle, production flow, storage and transportation, vaccination modalities, vaccinated subjects and so on. Multiple types of paper are included in this issue, including articles, reviews, case reports, letters and so on.

Guest Editor

Dr. Qing Ye

1. The Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310052, China
2. National Clinical Research Center for Child Health, Hangzhou 310052, China
3. National Children's Regional Medical Center, Hangzhou 310052, China

Deadline for manuscript submissions

closed (30 November 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/127409

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).